Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 41%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insulet is projected to achieve substantial revenue growth, with estimates of $2.7 billion in FY25 rising to $4.2 billion by FY28, reflecting a compound annual growth rate (CAGR) of 16.3%. The company has increased its 2025 total sales growth guidance to 28-29% year-over-year, indicating robust demand and a clear strategy to capture market share in the under-penetrated diabetes market. Additionally, Insulet's gross margin guidance of over 71% alongside an improved operating margin forecast, combined with a strong growth profile and competitive advantages, positions the company favorably for long-term financial success.

Bears say

Insulet is facing significant challenges, as evidenced by a projected decline in Drug Delivery revenue of 85-95% year-over-year, marking a sharp deterioration from previous expectations. Additionally, the company is experiencing slower-than-anticipated expansion in the U.S. market and increased competition, which poses serious risks to future growth and product adoption. Regulatory hurdles and uncertainties surrounding healthcare legislation further exacerbate the financial outlook, suggesting potential hurdles in achieving sustained profitability and revenue growth.

Insulet (PODD) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 41% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 17 analysts, Insulet (PODD) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $369.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $369.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.